Depression | Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder

Depression research study

What is the primary objective of this study?

Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state, and cognitive function.

Who is eligible to participate?

Inclusion Criteria: - Outpatients with neurological disorders and mild or moderate symptoms of depression with Hospital Anxiety Depression Scale (HADS) depression scale score of 8 and higher. Fevarin® prescribed not earlier than 7 days before Visit 1. Exclusion Criteria: - Labeled contraindications to Fevarin®, psychotic symptoms and/or suicidal ideation, schizophrenia, bipolar disorder, schizoaffective disorder, severe dementia, alcohol or drug abuse, acute neurological disorders.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?


Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Outpatients with neurological disorders and depression.Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.

Study Status


Start Date: January 2014

Completed Date: November 2015


Type: Observational


Primary Outcome: Prevalence of Different Neurological Disorders Associated With Depression Treated With Fluvoxamine (Fevarin®).

Secondary Outcome: Change in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score

Study sponsors, principal investigator, and references

Principal Investigator: Tatiana Vladimirova, MD, PhD

Lead Sponsor: Abbott

Collaborator: Manipal Acunova Ltd.

More information:

Discuss Fluvoxamine